[The influence of mepiprazol on monoamine metabolism in the rat CNS: demonstration of reduced norepinephrine activity and simultaneously enhanced serotonin and dopamine activities (author's transl)].
Biochemical studies of monamine turnover and neuronal reuptake indicate that mepiprazole, a novel psychotropic pyrazole derivative, decreases norepinephrine receptor activity and enhances serotonin and to a lower extent also dopamine activity in the rat CNS. It can be concluded that mepiprazole might be of value in the treatment of certain types of depression and might be helpful to alleviate side effects of L-dopa in the treatment of parkinsonism.
D000818:Animals; D001679:Biogenic Amines / Q000378:metabolism*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D008297:Male; D009638:Norepinephrine / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology*; D051381:Rats; D012701:Serotonin / Q000378:metabolism
D001679:Biogenic Amines; D010879:Piperazines; D011720:Pyrazoles; D012701:Serotonin; D004298:Dopamine; D009638:Norepinephrine
Der Einfluss von Mepiprazol auf den Monoaminstoffwechsel im ZNS der Ratte: Nachweis verminderter Noradrenalin-Aktivität unter gleichzeitig erhöhter Serotonin- und Dopamin-Aktivität